15969-08-1

Basic information

• Product Name: 2-METHOXY-6-NITROPHENOL
• Synonyms: 2-METHOXY-6-NITROPHENOL
• CAS NO: 15969-08-1
• Molecular Formula: C₇H₇NO₄
• Molecular Weight: 169.13478
• Mol File: 15969-08-1.mol

Chemical Properties

• Melting Point: 62 °C (sublm)
• Boiling Point: 260.3±20.0 °C(Predicted)
• Appearance: /
• Density: 1.367±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 7.09±0.24(Predicted)
• CAS DataBase Reference: 2-METHOXY-6-NITROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-6-NITROPHENOL(15969-08-1)
• EPA Substance Registry System: 2-METHOXY-6-NITROPHENOL(15969-08-1)

Safety Data

• Hazardous Substances Data: 15969-08-1(Hazardous Substances Data)

Usage

Uses

Used in Dye Manufacturing:
2-Methoxy-6-nitrophenol is used as a key intermediate in the production of dyes, contributing to the development of colorants for various applications.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 2-Methoxy-6-nitrophenol is employed as a precursor in the synthesis of certain drugs, playing a crucial role in the development of medicinal compounds.
Used in Organic Compound Synthesis:
2-Methoxy-6-nitrophenol serves as an intermediate in the synthesis of a range of organic chemicals, facilitating the creation of diverse chemical products.

Upstream product

• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 90-05-1 2-methoxy-phenol 
• 60-29-7 diethyl ether 
• 91004-48-7 4,5-Dimethoxy-3-nitrobenzoic acid 
• 62-53-3 aniline 
• 116496-81-2 acetic acid-(2-methoxy-6-nitro-anilide) 
• 555-03-3 3-nitroanisole 
• 110-71-4 1,2-dimethoxyethane 

Downstream Products

• 888731-94-0 (4-benzyloxy-3,5-dichlorophenyl)-[8-(tert-butyldimethylsilyloxy)-2,3-dihydrobenzo[1,4]oxazin-4-yl]-methanone 
• 888731-91-7 2-chloro-N-(2-hydroxy-3-methoxyphenyl)-acetamide 
• 258532-71-7 8-methoxy-4H-benzo[1,4]oxazin-3-one 
• 258532-76-2 8-hydroxy-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 663935-09-9 2-isopropoxy-3-methoxynitrobenzene 
• 158429-03-9 C₁₂H₁₅NO₄ 
• 6299-67-8 2,3-dimethoxyaniline 
• 25245-33-4 1-iodo-2,3-dimethoxybenzene 
• 220034-67-3 N-tosyldiscorhabdin C 
• 220034-62-8 {2-[7-Benzyloxy-6-methoxy-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-ethyl}-carbamic acid tert-butyl ester 
• 220034-66-2 C₂₅H₂₁N₃O₄S 
• 220034-64-0 7-(3,5-dibromo-4-hydroxyphenethylamino)-1-tosyl-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one 
• 220034-65-1 7-[2-(3-Bromo-4-hydroxy-phenyl)-ethylamino]-1-(toluene-4-sulfonyl)-3,4-dihydro-1H-pyrrolo[4,3,2-de]quinolin-8-one 
• 220034-59-3 7-(4-hydroxyphenethylamino)-1-tosyl-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one 

Relevant articles and documents

LIPOXYGENASE INHIBITORS

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

Water-soluble PDE4 inhibitors for the treatment of dry eye

PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, whic

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Nitration of substituted phenols by different efficient heterogeneous systems

Nitration of substituted phenols were carried out by the mixture of sodium nitrite and wet SiO2 (50% w/w) in the presence of four different efficient heterogeneous systems: 1) oxalic acid dihydrate (I), 2) sodium hydrogen sulphate (II), 3) aluminum hydrogen sulphate (III) and 4) silica sulphuric acid (IV) in CH2Cl2 at room temperature and high yields. Optimum conditions for theses systems and the regioselectivities of the reactions are reported.

Regio-selective mono nitration of phenols with ferric nitrate in room temperature ionic liquid

The mono nitration of phenols with ferric nitrate has been achieved in high regio-selectivities in 1-3 h at 30-60°C using the ionic liquid 1,3-di-n-butylimidazolium tetraflouroborate [bbim]BF4 as the solvent. In particular, excellent para selectives of the order of 76-86% for unsubstituted, ortho and meta-substituted phenols were observed.

Nitration of electron-rich aromatic compounds by cerium ammonium nitrate coated on silica

Treatment of electron-rich aromatic derivatives with cerium (IV) ammonium nitrate coated on silica (CANSio2) affords nitro aromatic compounds. The scope and the limitation of this reaction are discussed.

The nitration of electron-rich aromatics

The successful mononitration of a variety of electron-rich aromatic substrates is reported, employing either nitronium tetrafluoroborate or 'claycop' as the nitrating agent. Dinitration of four of the substrates was achieved when employing nitronium tetrafluoroborate. Several of the products have previously been prepared only by indirect methods.